The latest biotech news

News and Trends 13 Feb 2018

Watch Out Eli Lilly: Novo’s Diabetes Drug Ozempic Gets European Approval

Update (13/02/2018): The European Commission has given Novo Nordisk a market authorization for Ozempic (semaglutide), bringing the competition for Eli Lilly’s Trulicity over to Europe. Eli Lilly executives have said that they are not worried by Novo’s competition, and keep confident on the performance of Trulicity, which now tops 40% of the market share of diabetes drugs belonging […]

February 13, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 13 Feb 2018

Erytech’s ‘Armed’ Red Blood Cells Will be Tested Against Triple Negative Breast Cancer

Erytech will test its Graspa technology for the treatment of a second solid tumor indication, breast cancer, following its success in pancreatic cancer. French biotech Erytech has developed an exciting platform for the treatment of cancer called Graspa, which encapsulates L-asparaginase in red blood cells. The company is now organizing a Phase II study for its next disease […]

February 13, 2018 - 2 minutesmins - By Alex Dale

fast wound healing prevents infection2 1

News and Trends 13 Feb 2018

High-Speed Healing Could Prevent the Infection of Chronic Wounds

Swedish scientists have used bacteria to deliver a chemical into wounds that speeds up the healing process. This could help to prevent their infection with dangerous strains of resistant bacteria. Researchers at Uppsala University have identified a technique to accelerate the wound healing process and reduce the chance of infection. The study, published in PNAS, […]

February 13, 2018 - 3 minutesmins - By Alex Dale

News and Trends 12 Feb 2018

No Nonsense Boehringer Ingelheim Jettisons Failing Alzheimer’s Disease Drug

Boehringer Ingelheim has ditched its Alzheimer’s drug after it failed to meet the endpoints of a Phase II trial but will continue to look at it for the treatment of schizophrenia. One of Germany’s biggest pharma companies, Boehringer Ingelheim, has given up on the development of its Alzheimer’s drug, BI 409306, which underwent Phase II testing. The […]

February 12, 2018 - 3 minutesmins - By Alex Dale

News and Trends 12 Feb 2018

Healthcare-Biotech Partnership Pledges to Take its Type 2 Diabetes Treatment Worldwide

Swiss pharma Roivant has given French biotech Poxel €28M upfront to get involved with the development and commercialization of imeglimin, a new treatment for metabolic disorders like type 2 diabetes. Poxel uses its expertise in metabolism to develop drugs for the treatment of disorders like type 2 diabetes. Its candidate imeglimin has caught the eye of […]

February 12, 2018 - 3 minutesmins - By Alex Dale

News and Trends 12 Feb 2018

First Functioning Kidney Tissue Generated from Embryonic Stem Cells

Researchers at the University of Manchester have used embryonic stem cells to produce kidney tissue that can filter the blood to produce urine, which opens the door to personalized kidney transplants. Scientists at the University of Manchester have generated human kidney tissue from embryonic stem cells for the first time. The research, published in the journal Stem […]

February 12, 2018 - 3 minutesmins - By Alex Dale

News and Trends 10 Feb 2018

Superbugs: Fighting Antibiotic Resistance at the Science Museum

An exhibition at the Science Museum London features some of the deadliest superbugs on Earth and the stories of the people fighting against the threat of antibiotic resistance. It is estimated that, by 2050, 10 million people will die every year due to infections with antibiotic-resistant bacteria. Meaning that the numbers will be higher than […]

February 10, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 8 Feb 2018

GSK’s Company Starts Phase III Trials with Two-Drug HIV Treatment

ViiV Healthcare has just started a clinical trial to test if its two-drug regimen for HIV can work as well as current three-drug HIV treatment. Most antiretroviral treatments used to keep HIV at bay employ a combination of three different drugs, exposing patients to the long-term toxicity of three different compounds at once. London-based ViiV […]

February 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

janssen biotech theravance bowel inflammation

News and Trends 8 Feb 2018

Janssen Biotech Offers up to $1Bn to Irish Biotech for a Bowel Inflammation Drug

Janssen Biotech and Theravance Biopharma will develop together a drug to treat bowel inflammation diseases like ulcerative colitis and Crohn’s disease. Janssen Biotech has set its eyes on a drug candidate being developed by the Irish Theravance Biopharma. Both have entered an agreement to co-develop and commercialize the drug. In exchange, Theravance is getting $100M (€82M) […]

February 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 7 Feb 2018

Scottish CAR-T Biotech Adds Another Stellar Partner to Its Roster

TC Biopharm has signed a new pharma partner, the Japan-based NIPRO Corporation, who will give the biotech a leg up in the CAR-T game. Hot on the heels of the two huge CAR-T acquisitions of Juno and Kite, Japanese pharma NIPRO Corporation is planting a foot in the game by partnering with Scotland-based TC Biopharm […]

February 7, 2018 - 1 minutemin - By Evelyn Warner

News and Trends 7 Feb 2018

January Has Been the Best Month Ever for Biotech in Spain

Biotech in Spain has kicked off 2018 setting a record for the number of acquisitions and fundraisings and their total value combined. Early in January, the Japanese big pharma Takeda announced its intention to acquire TiGenix for €520M. The cell therapy biotech was born in 2011 as a merger of Belgian TiGenix and Spanish Cellerix, […]

February 7, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Feb 2018

Spring Cleaning: AstraZeneca Ditches Underperforming Asthma and Cancer Candidates

AstraZeneca has given up on the development of its PD-1 checkpoint inhibitor drug, which was the headline act when its subsidiary MedImmune acquired Amplimmune in 2013. There was no sentiment as pharma giant AstraZeneca cut a number of drugs from its pipeline after they did not perform as expected during clinical trials. The biggest name to get […]

February 6, 2018 - 3 minutesmins - By Alex Dale

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Watch Out Eli Lilly: Novo’s Diabetes Drug Ozempic Gets European Approval

Erytech’s ‘Armed’ Red Blood Cells Will be Tested Against Triple Negative Breast Cancer

High-Speed Healing Could Prevent the Infection of Chronic Wounds

No Nonsense Boehringer Ingelheim Jettisons Failing Alzheimer’s Disease Drug

Healthcare-Biotech Partnership Pledges to Take its Type 2 Diabetes Treatment Worldwide

First Functioning Kidney Tissue Generated from Embryonic Stem Cells

Superbugs: Fighting Antibiotic Resistance at the Science Museum

GSK’s Company Starts Phase III Trials with Two-Drug HIV Treatment

Janssen Biotech Offers up to $1Bn to Irish Biotech for a Bowel Inflammation Drug

Scottish CAR-T Biotech Adds Another Stellar Partner to Its Roster

January Has Been the Best Month Ever for Biotech in Spain

Spring Cleaning: AstraZeneca Ditches Underperforming Asthma and Cancer Candidates

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!